GlassScriptPhysician profile
Angelo Annaloro
NPI 1932169976
$2,441.13
in general payments reported to CMS, 2019-2025
31 companies · $319 in 2025
The $319 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $245 · 2021: $526 · 2022: $497 · 2023: $187 · 2024: $320 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $826.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $600.68 | 2019-2025 | Xtandi, Myrbetriq |
| Boston Scientific Corporation | $271.36 | 2021-2025 | General - Pain Management, Ams 800 Artificial Urinary Sphincter, Ams 700 Cxr Rte Kit |
| Abbvie INC. | $205.26 | 2021-2025 | |
| Urogen Pharma, INC. | $182.83 | 2021-2025 | Jelmyto |
| Janssen Biotech, INC. | $132.02 | 2019-2022 | |
| Tolmar Pharmaceuticals, INC. | $112.11 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $107.25 | 2024-2025 | Gemtesa, Orgovyx |
| Accord Healthcare, INC. | $97.83 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $79.02 | 2019-2022 | |
| Pfizer INC. | $72.01 | 2019-2024 | |
| Myovant Sciences INC. | $65.39 | 2021-2022 | |
| Antares Pharma, INC. | $53.71 | 2019-2025 | Xyosted |
| Dendreon Pharmaceuticals LLC | $50.89 | 2022-2024 | Provenge |
| Coloplast Corp | $50.61 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $34.45 | 2019-2024 | Adstiladrin |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $32.85 | 2020 | |
| Axonics, INC. | $30.99 | 2022-2023 | Bulkamid |
| Rochester Medical Corporation | $28.16 | 2019-2020 | |
| Laborie Medical Technologies Corp. | $26.92 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Procept Biorobotics Corporation | $25.72 | 2021 | |
| Dornier Medtech America, INC | $24.35 | 2019 | |
| Blue Earth Diagnostics | $21.58 | 2019 | |
| Merck Sharp & Dohme LLC | $21.08 | 2021 | |
| Olympus America INC. | $16.13 | 2025 | Itind System |
| Hollister Incorporated | $15.97 | 2023 | Infyna Chic |
| Kerecis Limited | $15.45 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Allergan, INC. | $14.74 | 2021 | |
| Ethicon US, LLC | $14.10 | 2020 | |
| Tolmar, INC. | $14.04 | 2024 | |
| Zyla Life Sciences, INC. | $12.44 | 2020 | |
| Mission Pharmacal Company | $11.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angelo Annaloro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.